Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer

Joanna N. Zamarbide Losada, Eric Sulpice, S. Combe, Gilberto S. Almeida, Damien A. Leach, Jaegul Choo, L. E. Protopapa, Margaret Hamilton, Sean E. McGuire, Xavier Gidrol, Charlotte L. Bevan, Claire FletcherJournal of Endocrinology 2023 · DOI

TL;DR

Researchers have identified a microRNA, miR-361-3p, that is overexpressed in breast cancer and contributes to drug resistance by suppressing apoptosis and promoting cell growth. Inhibiting miR-361-3p shows promise as a novel therapeutic strategy, effectively reducing tumor growth in preclinical models and even synergizing with existing treatments like PARP inhibitors.

What Problem Does This Paper Address?

Breast cancer (BC) remains a major health challenge, particularly for estrogen receptor-positive (ER+) subtypes where endocrine therapies like anti-estrogens and aromatase inhibitors (AIs) are standard. However, a significant hurdle is the development of resistance to these treatments, often linked to the dysregulation of apoptosis (programmed cell death). When apoptosis pathways are compromised, cancer cells can survive and proliferate despite therapy. This paper addresses the critical need for new therapeutic targets that can overcome this resistance, specifically by investigating the role of microRNAs (miRs) – small non-coding RNAs known to regulate gene expression and implicated in cancer progression and drug resistance. The authors aim to identify miRs that modulate apoptosis in both drug-responsive and drug-resistant breast cancer and explore their potential as therapeutic agents.

Methods

The study employed a multi-pronged approach:

  • High-throughput microRNA Inhibitor Screening: A library of 954 miR inhibitors was screened in ER+ breast cancer cell lines (MCF7) and their endocrine-resistant derivatives (LTED, TamR). High-content screening microscopy was used to quantify apoptotic markers and cell numbers.
  • In Vitro Validation: Promising miR inhibitors were further tested using assays like Caspase 3/7-Glo (for apoptosis activity), flow cytometry (for early apoptosis), and Sulforhodamine B (SRB) assays (for cell proliferation). Western blotting was used to assess protein level changes, including cleaved PARP1, a key apoptosis marker.
  • In Vivo Xenograft Models: The efficacy of a modified miR-361-3p inhibitor (ASO-361-3p) was evaluated in mouse models bearing human breast cancer xenografts. Tumor volume, animal weight, and miR-361-3p levels in tumors and other tissues were monitored. Immunohistochemistry was used to assess proliferation (MCM2) and apoptosis (cleaved PARP) markers in tumor tissues.
  • RNA Sequencing (RNA-seq): Differential gene expression analysis was performed on xenograft tumors to identify genes and pathways affected by miR-361-3p inhibition. Gene Set Enrichment Analysis (GSEA) was used to interpret these changes.
  • Bioinformatic Analysis: Publicly available datasets (TCGA and METABRIC) were analyzed to assess miR-361-3p expression in human breast tumors and its correlation with patient survival and molecular subtypes.
  • Patient-Derived Explants: The therapeutic potential of ASO-361-3p was tested in ex vivo cultures of human breast cancer tumor samples.
  • Drug Combination Studies: The synergistic effects of miR-361-3p inhibition with a PARP inhibitor (Olaparib) were investigated.

Datasets

  • Cell Lines: MCF7 (drug-responsive ER+), LTED (long-term estrogen-deprived resistant), TamR (tamoxifen-resistant), FulvR (fulvestrant-resistant), and MDA-MB-231 (ER-).
  • Publicly Available Datasets: TCGA-BRCA (The Cancer Genome Atlas Breast Cancer) and METABRIC (Molecular Taxonomy and Breast Cancer International Consortium) datasets were used for analyzing miR-361-3p expression in human tumors and correlating it with clinical outcomes.
  • Patient-Derived Explants: Tumor samples from BC patients undergoing surgery were used for ex vivo culture experiments.

Key Insights and Ideas

  • miR-361-3p as a "Master Regulator" of Resistance: The study strongly implicates miR-361-3p as a key player in breast cancer progression and resistance, not just by promoting proliferation but by actively suppressing apoptosis.
  • Dual Action: Apoptosis Induction and Proliferation Inhibition: The miR-361-3p inhibitor doesn't just kill cancer cells; it also stops them from growing, making it a potent dual-action therapeutic candidate.
  • Broad Efficacy Across Subtypes: The inhibitor shows effectiveness in various breast cancer subtypes, including endocrine-responsive, endocrine-resistant, and even ER-negative cells, suggesting a wide therapeutic window.
  • Mechanism Involves Cell Cycle Arrest and DNA Damage: The inhibition of miR-361-3p triggers a p53-mediated G1 cell cycle arrest and induces DNA damage, pointing to complex cellular responses that ultimately lead to cell death or growth inhibition.
  • FANCA as a Key Direct Target: The identification of FANCA as a direct target of miR-361-3p provides a crucial molecular link explaining how miR-361-3p influences cell growth and apoptosis.
  • Synergy with PARP Inhibitors: The finding that miR-361-3p inhibition enhances the efficacy of Olaparib (a PARP inhibitor) is particularly exciting, as it suggests a potential combination therapy that could overcome resistance to both agents.

Key Results

  • A high-throughput screen identified miR-361-3p inhibitor as significantly inducing apoptosis and reducing proliferation in multiple breast cancer cell lines, including drug-resistant ones.
  • In vivo studies showed that ASO-361-3p significantly reduced xenograft tumor volume in mice without overt toxicity.
  • RNA-seq analysis revealed that miR-361-3p inhibition impacts cell cycle progression, DNA repair, and EMT pathways.
  • miR-361-3p expression was found to be significantly higher in primary breast tumors compared to normal tissue and associated with decreased patient survival.
  • Treatment of patient-derived breast cancer explants with ASO-361-3p reduced miR-361-3p levels and Ki67 proliferation marker.
  • Combination therapy of miR-361-3p inhibitor and Olaparib demonstrated synergistic effects on inhibiting MCF7 cell growth.

Limitations and Future Work

  • In Vivo vs. In Vitro FANCA Modulation: The study noted discrepancies in FANCA transcript levels between short-term in vitro experiments (increased) and long-term in vivo experiments (decreased) with ASO-361-3p. This suggests that the mechanism of miR-361-3p inhibition might shift over time, potentially favoring proliferative repression over direct apoptotic induction in longer treatments. Further investigation into these temporal differences is warranted.
  • Targeted Delivery: While ASO-361-3p showed efficacy in reducing miR-361-3p levels in spleen and lungs, suggesting systemic distribution, the authors suggest further investigation into targeted delivery of ASOs to improve therapeutic specificity and minimize off-target effects.
  • Clinical Translation: While patient explants showed promising results, further preclinical studies are needed to fully establish the clinical utility of miR-361-3p inhibitor as a novel therapeutic for advanced breast cancer.
  • Broader Target Validation: The study identified FANCA as a direct target, but further validation of other identified direct targets and their contribution to the observed phenotype would be beneficial.
  • Mechanism of DNA Damage: While DNA damage was observed, the precise mechanism by which miR-361-3p inhibition induces it requires further elucidation.

Summary updated

Abstract

Breast cancer (BC) is the most diagnosed cancer in women worldwide. In estrogen receptor (ER)-positive disease, anti-estrogens and aromatase inhibitors (AI) improve patient survival; however, many patients develop resistance. Dysregulation of apoptosis is a common resistance mechanism; thus, agents that can reinstate the activity of apoptotic pathways represent promising therapeutics for advanced drug-resistant disease. Emerging targets in this scenario include microRNAs (miRs). To identify miRs modulating apoptosis in drug-responsive and -resistant BC, a high-throughput miR inhibitor screen was performed, followed by high-content screening microscopy for apoptotic markers. Validation demonstrated that miR-361-3p inhibitor significantly increases early apoptosis and reduces proliferation of drug-responsive (MCF7), plus AI-/antiestrogen-resistant derivatives (LTED, TamR, FulvR), and ER- cells (MDA-MB-231). Importantly, proliferation-inhibitory effects were observed in vivo in a xenograft model, indicating the potential clinical application of miR-361-3p inhibition. RNA-seq of tumour xenografts identified FANCA as a direct miR-361-3p target, and validation suggested miR-361-3p inhibitor effects might be mediated in part through FANCA modulation. Moreover, miR-361-3p inhibition resulted in p53-mediated G1 cell cycle arrest through activation of p21 and reduced BC invasion. Analysis of publicly available datasets showed miR-361-3p expression is significantly higher in primary breast tumours vspaired normal tissue and is associated with decreased overall survival. In addition, miR-361-3p inhibitor treatment of BC patient explants decreased levels of miR-361-3p and proliferation marker, Ki67. Finally, miR-361-3p inhibitor showed synergistic effects on BC growth when combined with PARP inhibitor, Olaparib. Together, these studies identify miR-361-3p inhibitor as a potential new treatment for drug-responsive and -resistant advanced BC.
BibTeX
@article{losada2023apoptosis,
  author = {Joanna N. Zamarbide Losada and Eric Sulpice and S. Combe and Gilberto S. Almeida and Damien A. Leach and Jaegul Choo and L. E. Protopapa and Margaret Hamilton and Sean E. McGuire and Xavier Gidrol and Charlotte L. Bevan and Claire Fletcher},
  title = {{Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer}},
  journal = {Journal of Endocrinology},
  year = {2023},
  doi = {10.1530/joe-22-0229},
}
Figure